Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ZFGN > SEC Filings for ZFGN > Form 8-K on 8-Mar-2016All Recent SEC Filings

Show all filings for ZAFGEN, INC.

Form 8-K for ZAFGEN, INC.


Change in Directors or Principal Officers, Regulation FD Disclosure, Financial State

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Election of Thomas O. Daniel, M.D. as a Director

On March 3, 2016, Zafgen, Inc. (the "Company") elected Thomas O. Daniel, M.D. to the Board of Directors of the Company (the "Board") as a Class I director, to serve until the Company's 2018 annual meeting of stockholders or until his successor is duly elected and qualified.

Dr. Daniel is currently Chairman, Celgene Research. He was President, Research and Early Development, for Celgene Corporation over the preceding nine years. He previously served as Chief Scientific Officer and Director of AmbRx Inc. a privately held biotechnology company delivering unique protein based biotherapeutics, and as Vice President, Research at Amgen Inc. Prior to Amgen's acquisition of Immunex, Dr. Daniel was Senior Vice President of Discovery Research at Immunex. He is currently a director of Juno Therapeutics, an innovator in the cellular therapy space, and serves as director of FerruMax and PharmAkea, two privately held biopharmaceutical companies. Dr. Daniel serves as a member of the Biomedical Science Advisory Board of Vanderbilt University Medical Center and is a member of the Therapeutic Advisory Board of aTyr Pharma, Inc. He also serves as co-chairman of the Biomedical Advisory Council of PhRMA. A nephrologist and former academic investigator, Dr. Daniel was previously the Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. He conducted research supported by the NIH and the Howard Hughes Medical Institute at UC San Francisco, earned an M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital.

As a non-employee director, Dr. Daniel will receive cash and equity compensation paid by the Company pursuant to its non-employee director compensation program upon the Board's approval. There are no arrangements or understandings between Dr. Daniel and any other person pursuant to which Dr. Daniel was elected as a director, and there are no transactions between Dr. Daniel and the Company that would require disclosure under Item 404(a) of Regulation S-K.

Item 7.01. Regulation FD Disclosure.

On March 8, 2016, the Company issued a press release announcing Dr. Daniel's appointment to the Board as discussed in Item 5.02(d) of this Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 hereto. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

No. Description

99.1 Press release issued by Zafgen, Inc. on March 8, 2016, furnished herewith.

  Add ZFGN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ZFGN - All Recent SEC Filings
Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.